Fusarium Allergy: Allergen, Keratitis Risk, and Why SCIT Lacks Evidence
Fusarium is a real allergen — Fus c 1 and Fus c 2 together identify 81% of sensitized patients — but it has three distinct clinical identities requiring different responses: an agricultural allergen with no SCIT RCT, the cause of the 2005–2006 contact-lens keratitis outbreak (164 CDC-confirmed US cases, 20× risk), and an invasive pathogen with near-100% mortality in persistently neutropenic patients.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Fusariumis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Fusarium Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to fusarium — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of fusarium allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of fusarium immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of fusarium extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for fusarium allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing fusarium extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription fusarium immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat fusarium allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Fusarium?
The biology, taxonomy, and clinical fingerprint of Fusarium — the foundation of how SCIT targets it.
Fusarium culmorum sickle-shaped macroconidia — the genus-defining morphology. Small microconidia (2–12 µm) are the primary airborne allergenic particles.
- Scientific name
- Fusarium solani / Fusarium oxysporum / Fusarium culmorum
- Family
- NectriaceaeHypocreales, Sordariomycetes, Ascomycota
- Type
- Soil and agricultural mold — seasonal with agricultural harvest peak; also a keratitis pathogen
- Native to
- Cosmopolitan; ubiquitous in soil, water, decaying organic matter, and grain storage worldwide
- Allergen proteins
- Fus c 1 (major) — 11 kDa ribosomal P2 protein; 35% IgE prevalence in sensitized patientsFus c 2 (major) — 13 kDa thioredoxin-like protein; 50% IgE prevalence in sensitized patientsFus c 3 — 15 kDa novel protein; 15% IgE prevalenceFus p 9 — vacuolar serine protease; cross-reacts with Pen ch 18, Asp f 18, Cla h 9
- Particle size
- Macroconidia 10–54 µm (sickle-shaped); microconidia 2–12 µm (both airborne)
- Avoidance difficulty
- Moderate
How Fusarium Allergy Presents
Symptoms by body system — useful for distinguishing Fusarium sensitivity from overlapping allergies and infections.
Respiratory
- Allergic rhinitis in sensitized grain-handling and agricultural workers
- Asthma exacerbation linked to grain-dust and Fusarium spore exposure at harvest
- Hypersensitivity pneumonitis documented in occupationally exposed grain handlers
- Perennial indoor rhinitis in patients with water-damaged building Fusarium exposure
Ocular
- Fusarium keratitis — CRITICAL: contact lens wearers with red painful eye need urgent fungal keratitis evaluation, not allergy testing
- Pain, photophobia, and vision loss in fungal keratitis — ophthalmology emergency, not an allergic condition
- Allergic conjunctivitis in IgE-sensitized patients during agricultural outdoor exposure
Dermal
- Skin prick test wheal-flare with non-standardized extract in sensitized patients
- Rare cutaneous fusariosis in immunocompromised patients — not IgE-mediated
- Contact dermatitis in occupational settings with heavy grain and soil Fusarium exposure
Systemic
- Invasive fusariosis in neutropenic patients: 40–70% mortality overall, approaching 100% in persistently neutropenic patients (Nucci, Clin Infect Dis 2007)
- Mycotoxin exposure (trichothecenes, fumonisins, zearalenone) via contaminated grain — separate from IgE allergy
- Disseminated skin lesions as hallmark of disseminated invasive fusariosis in immunocompromised hosts
Fusarium comes to me three different ways. A grain farmer with sneezing and wheezing at harvest — that is an IgE sensitization discussion, though SCIT evidence is absent. A contact-lens wearer with a red painful eye — that is a fungal keratitis emergency and they need same-day ophthalmology, not allergy shots. And a neutropenic leukemia patient with fever — that is invasive fusariosis, and we are calling infectious disease immediately. The allergy conversation only happens with the first patient.
When & Where Fusarium Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Airborne spore peak in late autumn during grain harvest; soil and water reservoir is year-round· Outdoor allergenic exposure peaks with agricultural harvest season (August–November in temperate zones)
US Exposure Map
11 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Moderate
- MT:
- Low
- ND:
- High
- MN:
- High
- WI:
- High
- MI:
- Moderate
- NY:
- Moderate
- MA:
- Low
- OR:
- Moderate
- ID:
- Low
- WY:
- Low
- SD:
- High
- IA:
- High
- IL:
- High
- IN:
- High
- OH:
- High
- PA:
- Moderate
- NJ:
- Low
- CT:
- Low
- RI:
- Low
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Moderate
- NE:
- High
- MO:
- High
- KY:
- Moderate
- WV:
- Low
- VA:
- Low
- MD:
- Low
- DE:
- Low
- AZ:
- Low
- NM:
- Low
- KS:
- High
- AR:
- Moderate
- TN:
- Moderate
- NC:
- Low
- SC:
- Low
- OK:
- Moderate
- LA:
- Low
- MS:
- Moderate
- AL:
- Moderate
- GA:
- Low
- TX:
- Moderate
- FL:
- Low
- AK:
- Low
- HI:
- Low
What Fusarium Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Fusarium cross-reactivity is driven primarily by the vacuolar serine protease Fus p 9 and the thioredoxin family (Fus c 2), creating significant IgE overlap with Aspergillus, Penicillium, and Cladosporium.
Asp f 18 / Fus p 9 vacuolar serine protease; thioredoxin (Asp f 28/29) cross-reacts with Fus c 2
Pen ch 18 / Fus p 9 vacuolar serine protease overlap (Chou H et al., Allergy 2008)
Sordariomycetes class overlap; documented cross-reactivity in mold-allergic atopic patient panels
Is SCIT Right for Your Fusarium Allergy?
Before discussing Fusarium allergy shots, this five-question assessment helps identify which Fusarium clinical scenario applies to you.
Do you wear contact lenses and have a current red, painful, or light-sensitive eye?
The Fusarium SCIT Protocol
Fusarium is included only in some mold-mix extracts in the US. Standalone Fusarium SCIT is essentially never prescribed, and if used in a mold-mix, must be in a separate vial from pollen extracts due to serine-protease degradation.
Fusarium SCIT is not a standalone practice-guideline recommendation. When Fusarium appears in a mold-only vial as part of a polysensitized patient's protocol, the same conservative build-up principles as other mold extracts apply: slower escalation, a mandatory 30-minute observation period, and immediate dose reduction at any systemic reaction. With Curex's at-home protocol you self-observe with a prescribed epinephrine auto-injector on hand, and the first injection from each new vial or concentration is Virtual Shot Room–supervised by the care team. Clinical use extrapolates from Alternaria precedent and Practice Parameter framework — no Fusarium-specific protocol exists.
Maintenance in mold-only vials separated from pollen extracts. Outcomes monitoring is by symptom response, not by validated Fusarium-specific endpoints.
No long-term data exists for Fusarium SCIT. Occupational exposure reduction should continue regardless of immunotherapy status — it remains the primary evidence-based intervention.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Fusarium SCIT
No controlled SCIT trial has been published for Fusarium. The efficacy bar below reflects only the context of the broader mold-SCIT evidence base — not Fusarium-specific data.
- Alternaria SCIT — combined score reduction at year 3 (only available mold-SCIT RCT for context)64%Kuna P et al., JACI 2011 — Alternaria precedent; no Fusarium-specific RCT exists
- Fus c 1 + Fus c 2 combined diagnostic capture of sensitized patients81%WHO/IUIS allergen nomenclature data for F. culmorum — diagnostic, not efficacy measure
No DBPC-RCT exists for Fusarium SCIT. The AAAAI/ACAAI Practice Parameter does not recommend Fusarium immunotherapy. For the allergically sensitized patient, exposure reduction (engineering controls, N95 masks during harvest) and pharmacotherapy are the evidence-supported interventions. For the contact-lens wearer, antifungal ophthalmology treatment is essential — SCIT is irrelevant to keratitis management.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Fusarium SCIT Side Effects
Fusarium mold extracts carry the same elevated systemic-reaction risk as other mold allergens in SCIT, with serine-protease (Fus p 9) activity contributing to larger local reactions when mixed with other allergens.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling and erythema | Rate 30–50% | Mild |
Large local reaction (>5 cm) Serine-protease activity in mold extracts amplifies local reactions | Rate 10–20% | Moderate |
Injection-site pruritus | Rate 20–40% | Mild |
Delayed local swelling | Rate 5–15% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis or mild asthma flare | Rate 0.5–2% of injections | Mild |
Generalized urticaria | Rate 0.1–0.5% of injections | Moderate |
Bronchospasm | Rate 0.05–0.15% of injections | Moderate |
Anaphylaxis Mandatory 30-minute self-observation after each at-home injection, with a prescribed epinephrine auto-injector on hand and the first injection from each new vial or concentration Virtual Shot Room–supervised | Rate <0.01% of injections | Severe |
Fusarium's serine-protease allergens (Fus p 9) that degrade pollen extracts in mixed vials also contribute to elevated local reaction rates. The mold-only separate-vial rule is mandatory for any Fusarium-containing protocol.
SCIT vs Alternatives for Fusarium
For Fusarium-sensitized patients, occupational exposure control — engineering controls, respiratory protection, and work-practice modifications — has more evidence than SCIT and should be the primary management strategy.
| Criterion | SCIT | SLIT Drops | Occupational ControlsBest | Medications |
|---|---|---|---|---|
| Effectiveness | No controlled evidence for Fusarium | No Fusarium SLIT trial data | Proven to reduce exposure below symptom threshold | Good for symptom control during harvest season |
| 5-yr cost | $3,500–$15,000 total | program quote required via Curex | Employer-borne engineering cost | $500–$2,000/year |
| Duration | 3–5 years | 3–5 years typical | Ongoing — part of workplace safety | Every season indefinitely |
| Convenience | Weekly then maintenance visits | Daily at-home drops | Part of work practice — no clinic visits | Daily pills and sprays |
| Safety | Elevated mold-extract reaction rate | Low systemic risk | No injection risk | Generally safe |
| Lasting effect | Unknown | Unknown | Sustained with continued controls | No disease modification |
SCIT
SLIT Drops
Occupational ControlsBest
Medications
Engineering controls and respiratory protection are the most evidence-based interventions for occupationally Fusarium-exposed patients. Curex delivers immunotherapy as weekly at-home self-injections with pricing confirmed in a current program quote for patients seeking an at-home option as an adjunct, with allergist oversight via telehealth, a prescribed epinephrine auto-injector confirmed on hand, and Virtual Shot Room–supervised dosing for the first injection from each new vial or concentration — though no controlled Fusarium immunotherapy data exists, and a physician-supervised safety review is essential before starting any mold immunotherapy.
What Fusarium SCIT Actually Costs
Fusarium SCIT as a standalone indication is unlikely to receive insurance coverage given the absence of practice-guideline support; inclusion in a broader mold-mix protocol may be coverable under standard allergy immunotherapy benefits if accompanied by documented polysensitization and failed pharmacotherapy. Curex at-home IgE testing identifies specific fusarium sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your fusarium allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Fusarium SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
In 2005–2006, Fusarium solani caused a major outbreak of contact-lens keratitis linked to Bausch and Lomb ReNu with MoistureLoc contact lens solution. CDC confirmed 164 cases in the United States, with more than 250 cases worldwide. Contact lens users of the implicated solution were 20 times more likely to develop fungal eye infection. Bausch and Lomb ultimately recalled the product and settled approximately 600 product-liability lawsuits for more than 250 million dollars (Chang DC et al., JAMA 2006). Fusarium keratitis presents as a red, painful eye with photophobia — it is an ophthalmological emergency requiring antifungal eye drops (natamycin, voriconazole) and immediate specialist care. It is not an allergy and is not treated with allergy shots.
No — Fusarium keratitis is an infectious process caused by the mold physically invading corneal tissue, not an IgE-mediated allergic reaction. Allergy shots work by modifying the immune system's IgE response to inhaled allergens — they have no effect on fungal infections and offer no protection against keratitis. If you wear contact lenses, the evidence-based prevention for Fusarium keratitis is proper lens hygiene (replacing lens cases monthly, using fresh solution, never topping off used solution), avoiding contact lens wear in water (swimming, showers), and using daily disposable lenses when possible. If you have a red painful eye while wearing contacts, remove the lens and seek same-day ophthalmology evaluation.
Fus c 1 (11 kDa ribosomal P2 protein) and Fus c 2 (13 kDa thioredoxin-like protein) are the two WHO/IUIS-recognized major allergens of Fusarium culmorum. Individually, Fus c 1 is positive in 35% and Fus c 2 in 50% of sensitized patients. Combined, they capture 81% of Fusarium-sensitized individuals — a useful diagnostic combination. Fus c 2 belongs to the thioredoxin protein family, which is conserved across many organisms including Aspergillus (Asp f 28/29), meaning some cross-reactivity with other molds is expected. A positive whole-extract Fusarium IgE without confirmed Fus c 1 or Fus c 2 positivity may reflect pan-fungal serine-protease cross-reactivity rather than true primary Fusarium sensitization.
Agricultural workers exposed to grain dust and Fusarium-contaminated soil during harvest should prioritize occupational exposure control. Engineering controls include enclosed tractor cabs with filtered air, enclosed grain handling and storage systems, and dust-suppression measures. Personal protective equipment should include N95 respirators or better during high-dust activities like harvesting, threshing, and grain handling. Medical surveillance — annual lung function testing and symptom questionnaires — is appropriate for heavily exposed workers. Standard pharmacotherapy (antihistamines, nasal corticosteroids, inhaled bronchodilators for asthma) manages symptoms during high-exposure periods. SCIT is not evidence-supported for Fusarium, and occupational hygiene controls are the primary intervention per occupational medicine guidelines.
No — Fusarium mycotoxins and Fusarium allergy are completely different biological phenomena. Fusarium allergy is an IgE-mediated immune response to Fusarium proteins (Fus c 1, Fus c 2, Fus p 9), triggered by inhaling spores. Mycotoxins are secondary metabolites produced by Fusarium under specific conditions — primarily affecting ingested grain rather than inhaled spores. The main Fusarium mycotoxins are trichothecenes (deoxynivalenol, also called DON or vomitoxin), fumonisins (IARC Group 2B carcinogen), and zearalenone (estrogenic at high doses). Mycotoxin exposure from contaminated grain primarily affects gastrointestinal health at high doses. In typical building and agricultural environments, airborne mycotoxin concentrations from Fusarium spores are generally far below toxic thresholds. A person can be IgE-sensitized to Fusarium proteins without meaningful mycotoxin exposure, and vice versa.
Coverage for Fusarium SCIT as a standalone indication is unlikely given that the AAAAI/ACAAI Practice Parameter does not endorse it as standard care. If Fusarium is included as part of a broader mold-mix polysensitization SCIT protocol alongside other better-evidenced allergens, the overall protocol may be billable under standard allergy immunotherapy CPT codes (95115, 95117, 95165) if a board-certified allergist documents positive Fusarium IgE testing, failed pharmacotherapy, and relevant clinical history. Prior authorization requirements vary by insurer and plan; a letter of medical necessity may be required. Contact your insurer before beginning any mold-mix SCIT protocol to confirm coverage terms.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.